JP2015525209A - 脂質ナノ粒子組成物と、それを作製する方法、及びそれを使用する方法 - Google Patents

脂質ナノ粒子組成物と、それを作製する方法、及びそれを使用する方法 Download PDF

Info

Publication number
JP2015525209A
JP2015525209A JP2015514192A JP2015514192A JP2015525209A JP 2015525209 A JP2015525209 A JP 2015525209A JP 2015514192 A JP2015514192 A JP 2015514192A JP 2015514192 A JP2015514192 A JP 2015514192A JP 2015525209 A JP2015525209 A JP 2015525209A
Authority
JP
Japan
Prior art keywords
lipid
mir
lipid nanoparticle
gln
lac
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015514192A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015525209A5 (enExample
Inventor
リー，ロバート・ジェイ
Original Assignee
ジ・オハイオ・ステート・ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジ・オハイオ・ステート・ユニバーシティ filed Critical ジ・オハイオ・ステート・ユニバーシティ
Publication of JP2015525209A publication Critical patent/JP2015525209A/ja
Publication of JP2015525209A5 publication Critical patent/JP2015525209A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21064—Peptidase K (3.4.21.64)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2015514192A 2012-05-23 2013-05-23 脂質ナノ粒子組成物と、それを作製する方法、及びそれを使用する方法 Pending JP2015525209A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261650729P 2012-05-23 2012-05-23
US61/650,729 2012-05-23
US201361784892P 2013-03-14 2013-03-14
US61/784,892 2013-03-14
PCT/US2013/042458 WO2013177419A2 (en) 2012-05-23 2013-05-23 Lipid nanoparticle compositions and methods of making and methods of using the same

Publications (2)

Publication Number Publication Date
JP2015525209A true JP2015525209A (ja) 2015-09-03
JP2015525209A5 JP2015525209A5 (enExample) 2016-03-17

Family

ID=48539454

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015514189A Expired - Fee Related JP6220389B2 (ja) 2012-05-23 2013-05-23 アンチセンスオリゴヌクレオチドを送達するための脂質ナノ粒子組成物
JP2015514192A Pending JP2015525209A (ja) 2012-05-23 2013-05-23 脂質ナノ粒子組成物と、それを作製する方法、及びそれを使用する方法
JP2015514193A Active JP6228191B2 (ja) 2012-05-23 2013-05-23 脂質コートされたアルブミンナノ粒子組成物と、それを作製する方法、及びそれを使用する方法
JP2017191221A Pending JP2018002727A (ja) 2012-05-23 2017-09-29 アンチセンスオリゴヌクレオチドを送達するための脂質ナノ粒子組成物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2015514189A Expired - Fee Related JP6220389B2 (ja) 2012-05-23 2013-05-23 アンチセンスオリゴヌクレオチドを送達するための脂質ナノ粒子組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015514193A Active JP6228191B2 (ja) 2012-05-23 2013-05-23 脂質コートされたアルブミンナノ粒子組成物と、それを作製する方法、及びそれを使用する方法
JP2017191221A Pending JP2018002727A (ja) 2012-05-23 2017-09-29 アンチセンスオリゴヌクレオチドを送達するための脂質ナノ粒子組成物

Country Status (10)

Country Link
US (4) US10307490B2 (enExample)
EP (3) EP2852380A4 (enExample)
JP (4) JP6220389B2 (enExample)
KR (3) KR20150032945A (enExample)
CN (3) CN104428005B (enExample)
AU (4) AU2013266238B2 (enExample)
BR (2) BR112014027834A2 (enExample)
CA (3) CA2874495A1 (enExample)
MX (3) MX2014014196A (enExample)
WO (3) WO2013177421A2 (enExample)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015519346A (ja) * 2012-05-23 2015-07-09 ジ・オハイオ・ステート・ユニバーシティ アンチセンスオリゴヌクレオチドを送達するための脂質ナノ粒子組成物
JP2019535808A (ja) * 2016-10-17 2019-12-12 南京▲緑▼叶制▲薬▼有限公司 ｂｃｌ−２を抑制するアンチセンスオリゴヌクレオチドの脂質ナノ粒子及びその調製方法
JP2020512282A (ja) * 2016-12-02 2020-04-23 タイガ バイオテクノロジーズ，インク． ナノ粒子製剤
US10786534B2 (en) 2013-03-11 2020-09-29 Taiga Biotechnologies, Inc. Production and use of red blood cells
US10864259B2 (en) 2017-08-03 2020-12-15 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US10953048B2 (en) 2012-07-20 2021-03-23 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
JP2021526505A (ja) * 2018-04-18 2021-10-07 オイシン バイオテクノロジーズ，インク． 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法
JP2021535227A (ja) * 2018-09-04 2021-12-16 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 核酸を臓器特異的送達するための組成物および方法
US11369678B2 (en) 2008-08-28 2022-06-28 Taiga Biotechnologies, Inc. Compositions and methods for modulating immune cells
US11667695B2 (en) 2008-05-16 2023-06-06 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US12250943B2 (en) 2019-04-08 2025-03-18 Htyr Acquisition Llc Compositions and methods for the cryopreservation of immune cells
US12370217B2 (en) 2019-05-14 2025-07-29 Htyr Acquisition Llc Compositions and methods for treating T cell exhaustion

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2821992A1 (en) 2010-10-01 2012-04-05 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
HRP20220250T1 (hr) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe
SI2791160T1 (sl) 2011-12-16 2022-07-29 Modernatx, Inc. Sestave modificirane MRNA
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
AU2013243952A1 (en) 2012-04-02 2014-10-30 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
SMT202200337T1 (it) 2012-11-26 2022-09-14 Modernatx Inc Rna modificato al livello del terminale
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
DK2992874T3 (en) 2013-04-30 2018-11-12 Delta Fly Pharma Inc LIPOSOM FOR TOPIC SUBMISSION AND USE THEREOF
US9802967B2 (en) * 2013-06-17 2017-10-31 The University Of North Carolina At Chapel Hill Polymer coated particles and methods thereof
ES2750608T3 (es) 2013-07-25 2020-03-26 Exicure Inc Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015130584A2 (en) * 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
WO2015154002A1 (en) * 2014-04-04 2015-10-08 Ohio State Innovation Foundation Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same
WO2015175965A1 (en) 2014-05-15 2015-11-19 The Research Foundation For Suny Compositions targeting the interaction domain between p27kip1 and brk and methods of use thereof
CA2953216C (en) 2014-06-04 2020-12-22 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
US12264344B2 (en) 2014-08-19 2025-04-01 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
AU2015337909B2 (en) * 2014-10-30 2018-12-13 Delta-Fly Pharma, Inc. New production method of lipoplex for local administration and antitumor drug using lipoplex
EP3220895B1 (en) 2014-11-21 2022-08-31 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
EP3247796A4 (en) * 2015-01-14 2018-07-11 Exicure, Inc. Nucleic acid nanostructures with core motifs
WO2016160822A1 (en) * 2015-03-30 2016-10-06 Verily Life Sciences Llc Functionalized nanoparticles, methods and in vivo diagnostic system
WO2016165825A1 (en) 2015-04-13 2016-10-20 Curevac Ag Method for producing rna compositions
KR20190118688A (ko) * 2015-06-05 2019-10-18 미라젠 세러퓨틱스 인코포레이티드 피부 t 세포 림프종(ctcl) 치료용 mir-155 억제제
CA2998810A1 (en) 2015-09-17 2017-03-23 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
CN105288647B (zh) * 2015-10-10 2018-05-25 中国药科大学 功能化白蛋白及其纳米制剂的制备方法
ES2924407T3 (es) * 2015-12-10 2022-10-06 Modernatx Inc Composiciones y procedimientos para el suministro de agentes terapéuticos
SMT202200252T1 (it) 2015-12-22 2022-07-21 Modernatx Inc Composti e composizioni per il rilascio intracellulare di agenti
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
US12491261B2 (en) 2016-10-26 2025-12-09 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
US20200069594A1 (en) * 2016-12-09 2020-03-05 Board Of Regents, The University Of Texas System Hybrid exosomal-polymeric (hexpo) nano-platform for delivery of rnai therapeutics
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
KR102568559B1 (ko) 2016-12-14 2023-08-18 얀센 바이오테크 인코포레이티드 Cd8a-결합 섬유결합소 iii형 도메인
US10611823B2 (en) 2016-12-14 2020-04-07 Hanssen Biotech, Inc CD137 binding fibronectin type III domains
CN109996569B (zh) * 2016-12-22 2022-05-03 百多力股份公司 用于医疗装置的药物释放涂层及其制备方法
US20180179577A1 (en) * 2016-12-22 2018-06-28 Jiaming HU Lipid-polymer Hybrid Nanoparticle Biochip and Application Thereof
US20190328903A1 (en) * 2016-12-30 2019-10-31 Samyang Biopharmaceuticals Corporation Polymer nanoparticle composition for plasmid dna delivery, and preparation method therefor
EP3596041B1 (en) 2017-03-15 2022-11-02 ModernaTX, Inc. Compound and compositions for intracellular delivery of therapeutic agents
AU2018234814B2 (en) 2017-03-15 2022-06-30 Modernatx, Inc. Crystal forms of amino lipids
AU2018234828A1 (en) 2017-03-15 2019-09-19 Modernatx, Inc. Lipid nanoparticle formulation
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
WO2018201090A1 (en) 2017-04-28 2018-11-01 Exicure, Inc. Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CN107184552B (zh) * 2017-06-07 2021-03-30 东华大学 一种半乳糖化聚乙烯亚胺修饰的载药醇质体的制备方法
WO2018232120A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
WO2018232357A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna formulations
JP7231147B2 (ja) * 2017-06-29 2023-03-01 国立大学法人東海国立大学機構 Ｒｎａ導入試薬及びその利用
EP3655776A2 (en) * 2017-07-18 2020-05-27 Avectas Limited Payload delivery across cell membranes using continuous flow fluidic system
WO2019040516A1 (en) * 2017-08-22 2019-02-28 Rubius Therapeutics, Inc. METHODS AND COMPOSITIONS OF LIPID NANOPARTICLES FOR THE PRODUCTION OF MODIFIED ERYTHROID CELLS
US11744801B2 (en) 2017-08-31 2023-09-05 Modernatx, Inc. Methods of making lipid nanoparticles
CN107982537A (zh) * 2017-11-17 2018-05-04 厦门大学 针对microRNA-155的治疗性药物及其应用
KR102245539B1 (ko) * 2018-02-12 2021-04-29 주식회사 지앤피바이오사이언스 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물
US12280114B2 (en) 2018-03-29 2025-04-22 Institute Of Basic Medical Sciences Extraction of plant source “medicinal soup” and manual preparation of “herbal medicine” and related products
WO2019222379A1 (en) * 2018-05-15 2019-11-21 Flagship Pioneering Innovations Vi, Llc. Pest control compositions and uses thereof
CN112423738B (zh) * 2018-06-01 2023-06-20 西江大学校产学协力团 通过利用脂质的表面改性提升细胞内摄取效率的纳米粒子复合体及其制造方法
US10987428B2 (en) * 2018-06-01 2021-04-27 City Of Hope Phosphorothioate-conjugated miRNAs and methods of using the same
US12357580B2 (en) 2018-06-19 2025-07-15 The Board Of Regents Of The University Of Texas System Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
CN108743962B (zh) * 2018-06-19 2021-07-02 东华大学 一种基于荧光碳点修饰的树状大分子的双载药靶向纳米平台的制备方法
GB2600800B (en) * 2018-09-04 2023-08-16 Univ Texas Compositions and methods for organ specific delivery of nucleic acids
WO2020061367A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
AU2020204989A1 (en) * 2019-01-04 2021-07-08 Elevatebio Technologies, Inc. Encapsulated RNA polynucleotides and methods of use
US11066355B2 (en) 2019-09-19 2021-07-20 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
WO2021076546A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Cd71 binding fibronectin type iii domains
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
US12491255B2 (en) 2019-10-14 2025-12-09 Aro Biotherapeutics Company EPCAM binding fibronectin type III domains
CN110638759A (zh) * 2019-10-29 2020-01-03 珠海丽凡达生物技术有限公司 一种用于体外转染和体内递送mRNA的制剂
KR102198736B1 (ko) * 2020-01-15 2021-01-05 이화여자대학교 산학협력단 생체 내 약물 전달을 위한 지질 나노입자 및 이의 용도
CN115243724B (zh) * 2020-02-19 2025-10-21 纳米医疗有限公司 可用于治疗癌症的经调配和/或共调配的含有TFGβ拮抗剂前药的脂质体组合物和其方法
CA3189338A1 (en) 2020-07-16 2022-01-20 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
WO2022036170A1 (en) * 2020-08-14 2022-02-17 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
WO2022192674A1 (en) * 2021-03-11 2022-09-15 The Trustees Of The University Of Pennsylvania Targeted therapeutic lipid nanoparticles and methods of use
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
US12239710B2 (en) 2021-04-14 2025-03-04 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
WO2023070132A1 (en) * 2021-10-22 2023-04-27 Ohio State Innovation Foundation Immunotherapies for the treatment of cancer
WO2023079553A1 (en) * 2021-11-03 2023-05-11 Biond Biologics Ltd. Intracellular delivery compositions
WO2023114943A2 (en) 2021-12-16 2023-06-22 Acuitas Therapeutics, Inc. Lipids for use in lipid nanoparticle formulations
CN114306369B (zh) * 2021-12-23 2023-12-26 北京悦康科创医药科技股份有限公司 一种硫代寡核苷酸注射液及其制备方法
WO2023192503A1 (en) * 2022-03-30 2023-10-05 The Johns Hopkins University Compositions of lipid nanoparticles for plasmid dna delivery to the liver and methods for preparing the same
WO2024044370A1 (en) * 2022-08-25 2024-02-29 Ohio State Innovation Foundation Compositions and methods for the delivery of active agents including nucleic acids
WO2024050310A1 (en) * 2022-08-29 2024-03-07 Sorrento Therapeutics, Inc. Lipid-coated nanoparticles
WO2024136219A1 (ko) * 2022-12-19 2024-06-27 주식회사 포스테라헬스사이언스 나노 입자를 포함하는 흡입 제형 및 이의 제조 방법
CN121013733A (zh) * 2023-03-31 2025-11-25 白橡树集团公司 Archexin的脂质体组合物
WO2025034965A1 (en) * 2023-08-09 2025-02-13 Board Of Regents, The University Of Texas System Targeted therapeutic delivery of lipid nanoparticles
TWI880568B (zh) * 2024-01-04 2025-04-11 訊聯生物科技股份有限公司 包含生物巨分子及奈米載體之組合物、包含其的醫藥組成物及其用途
WO2025171027A1 (en) * 2024-02-05 2025-08-14 University Of Rhode Island Board Of Trustees Phlip ®-lnp for targeted intracellular delivery of nucleic acid therapeutics
US20250297260A1 (en) 2024-03-22 2025-09-25 Takeda Pharmaceutical Company Limited Compositions and methods for inhibiting cytochrome p450 family 7 subfamily a member 1 (cyp7a1) expression

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003088371A (ja) * 2001-09-04 2003-03-25 Mitsubishi Pharma Corp 遺伝子導入用組成物
JP2005516897A (ja) * 2001-11-07 2005-06-09 イネックス ファーマシューティカルズ コーポレイション 改善された粘膜のワクチン及びその使用方法
JP2007505954A (ja) * 2003-09-15 2007-03-15 プロチバ バイオセラピューティクス インコーポレイティッド ポリエチレングリコール修飾脂質化合物およびその使用
JP2013511291A (ja) * 2009-11-23 2013-04-04 ジ・オハイオ・ステート・ユニバーシティ 腫瘍細胞の増殖、遊走および浸潤に影響を与えるために有用な物質および方法
JP2013523126A (ja) * 2010-03-26 2013-06-17 ジ・オハイオ・ステート・ユニバーシティ ｍｉＲ−１５５によるミスマッチ修復およびゲノム安定性の調節に関連する材料および方法

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US590877A (en) * 1897-09-28 Danger-signal for railway-crossings
US2003203A (en) * 1933-05-15 1935-05-28 Kim Young Wo Game
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ATE155681T1 (de) 1992-05-18 1997-08-15 Minnesota Mining & Mfg Einrichtung zur transmucosalen wirkstoffabgabe
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US20020022264A1 (en) * 1995-05-26 2002-02-21 Sullivan Sean M. Delivery vehicles comprising stable lipid/nucleic acid complexes
US5908777A (en) * 1995-06-23 1999-06-01 University Of Pittsburgh Lipidic vector for nucleic acid delivery
US6248720B1 (en) * 1996-07-03 2001-06-19 Brown University Research Foundation Method for gene therapy using nucleic acid loaded polymeric microparticles
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
EP1017365B1 (en) * 1997-06-23 2003-12-10 Sequus Pharmaceuticals, Inc. Liposome-entrapped polynucleotide composition and method
US6395253B2 (en) * 1998-04-23 2002-05-28 The Regents Of The University Of Michigan Microspheres containing condensed polyanionic bioactive agents and methods for their production
ATE324888T1 (de) * 1999-06-14 2006-06-15 Cancer Rec Tech Ltd Krebstherapie
WO2001015726A2 (en) * 1999-08-27 2001-03-08 Inex Pharmaceuticals Corp. Compositions for stimulating cytokine secretion and inducing an immune response
US7060291B1 (en) 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
AU2001255260A1 (en) 2000-04-07 2001-10-23 Baylor College Of Medicine Macroaggregated protein conjugates as oral genetic immunization delivery agents
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
EP1383480A4 (en) * 2001-04-30 2006-05-24 Targeted Genetics Corp Lipid-Containing Drug Delivery Complexes and Method of Producing the Same
US7514098B2 (en) 2001-05-30 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Use of targeted cross-linked nanoparticles for in vivo gene delivery
KR100484371B1 (ko) 2001-10-25 2005-04-20 가부시키가이샤 아텍스 히터선부착 시트체의 제조방법
US7678386B2 (en) 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
KR101076146B1 (ko) * 2002-08-16 2011-10-21 렉산 팔마큐티칼스, 인크. 사람의 Ａｋｔ-1 유전자의 발현을 저해하는 안티센스 올리고뉴클레오타이드의 용도
WO2004064731A2 (en) 2003-01-14 2004-08-05 University Of Washington Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymlplhoid tissues
AU2004207576B8 (en) 2003-01-28 2008-11-20 Rexahn Pharmaceuticals, Inc. Antisense oligonucleotides that inhibit expression of HIF-1
DE602004022921D1 (de) 2003-01-31 2009-10-15 Rexahn Corp Antisense oligonukleotide, die die ausprägungsstufe von hif-1 hemmen
KR100638041B1 (ko) 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
JP2006111591A (ja) * 2004-10-15 2006-04-27 Anges Mg Inc 核酸医薬を標的特異的に細胞内送達するための製剤
JP2006298780A (ja) * 2005-04-15 2006-11-02 Tohoku Univ Ｈｇｆ遺伝子と粗大凝集アルブミン−ポリエチレンイミン（ｍａａ−ｐｅｉ）との複合体
US20070087045A1 (en) * 2005-10-14 2007-04-19 Industrial Technology Research Institute Lipid carrier and method of preparing the same
TW200800235A (en) * 2005-10-18 2008-01-01 Otsuka Pharma Co Ltd Carrier composition for nucleic acid transport
US8101741B2 (en) 2005-11-02 2012-01-24 Protiva Biotherapeutics, Inc. Modified siRNA molecules and uses thereof
US8067380B2 (en) 2005-12-19 2011-11-29 Industrial Technology Research Institute Glutathione-based delivery system
GB2450475A (en) * 2007-06-12 2008-12-31 Univ Nottingham Trent Antimicrobial polymer nanocomposite
US20110177155A1 (en) * 2007-08-21 2011-07-21 Immune Disease Institute, Inc. Methods of delivery of agents to leukocytes and endothelial cells
PL208054B1 (pl) * 2007-09-06 2011-03-31 Akademia Medyczna Im Piastow Śląskich We Wrocławiu Kompozycja lipidowa do wytwarzania lipidowego nośnika dla leków genetycznych i jej zastosowanie
WO2009051451A2 (en) * 2007-10-17 2009-04-23 Korea Advanced Institute Of Science And Technology Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same
US20100285111A1 (en) * 2007-11-09 2010-11-11 Northeastern University Self-assembling micelle-like nanoparticles for systemic gene delivery
US8916531B2 (en) * 2007-11-20 2014-12-23 Isis Pharmaceuticals, Inc. Modulation of CD40 expression
US20110038941A1 (en) 2007-12-27 2011-02-17 The Ohio State University Research Foundation Lipid Nanoparticle Compositions and Methods of Making and Using the Same
ES2685464T3 (es) 2008-04-04 2018-10-09 The Regents Of The University Of California Nanopartículas magnéticas funcionalizadas y métodos de uso de las mismas
US8222220B2 (en) 2008-05-13 2012-07-17 George Mason Intellectual Properties, Inc. Nanogenomics for medicine: siRNA engineering
US8389768B2 (en) * 2008-05-19 2013-03-05 The University Of North Carolina At Chapel Hill Methods and compositions comprising novel cationic lipids
US20090312402A1 (en) * 2008-05-20 2009-12-17 Contag Christopher H Encapsulated nanoparticles for drug delivery
JP2011528910A (ja) * 2008-07-25 2011-12-01 アルニラム ファーマスーティカルズ インコーポレイテッド センス鎖中の一般塩基またはミスマッチを使用したｓｉＲＮＡサイレンシング活性の亢進
US20110280913A1 (en) 2008-07-31 2011-11-17 The Ohio State University Methods and Compositions for Delivering Therapeutic Agents in the Treatment of B-Cell Related Disorders
WO2010049562A1 (es) * 2008-10-28 2010-05-06 Universidade De Santiago De Compostela Sistemas nanoparticulares elaborados a base de polímeros aniónicos.
WO2010054384A1 (en) * 2008-11-10 2010-05-14 Alnylam Pharmaceuticals, Inc. Lipids and compositions for the delivery of therapeutics
EP2210589B1 (en) 2009-01-22 2015-05-06 Ludwig-Maximilians-Universität München Vesicular phospholipid gels comprising proteinaceous substances
ES2351756B1 (es) 2009-07-28 2011-10-05 Universidad Del Pais Vasco Nanopartículas lipídicas para terapia génica.
CA2794307A1 (en) * 2010-03-26 2011-09-29 Mersana Therapeutics, Inc. Modified polymers for delivery of polynucleotides, method of manufacture, and methods of use thereof
EP2561072A4 (en) * 2010-04-20 2016-04-06 Univ Florida NANOZYME, METHOD FOR THE PRODUCTION OF NANOCYMENTS AND METHOD FOR THE USE OF NANOCYMENTS
US20130260460A1 (en) * 2010-04-22 2013-10-03 Isis Pharmaceuticals Inc Conformationally restricted dinucleotide monomers and oligonucleotides
US20110319473A1 (en) * 2010-06-29 2011-12-29 Surmodics, Inc. Compositions and methods for enhancement of nucleic acid delivery
US8691750B2 (en) 2011-05-17 2014-04-08 Axolabs Gmbh Lipids and compositions for intracellular delivery of biologically active compounds
CN102552105B (zh) * 2011-10-17 2014-04-02 复旦大学 一种级联脑部靶向药物递送系统及其制备方法和用途
BR112014027834A2 (pt) 2012-05-23 2017-08-08 Univ Ohio State composições de nanopartícula lipídica para entrega de oligonucleotídeos antissenso

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003088371A (ja) * 2001-09-04 2003-03-25 Mitsubishi Pharma Corp 遺伝子導入用組成物
JP2005516897A (ja) * 2001-11-07 2005-06-09 イネックス ファーマシューティカルズ コーポレイション 改善された粘膜のワクチン及びその使用方法
JP2007505954A (ja) * 2003-09-15 2007-03-15 プロチバ バイオセラピューティクス インコーポレイティッド ポリエチレングリコール修飾脂質化合物およびその使用
JP2013511291A (ja) * 2009-11-23 2013-04-04 ジ・オハイオ・ステート・ユニバーシティ 腫瘍細胞の増殖、遊走および浸潤に影響を与えるために有用な物質および方法
JP2013523126A (ja) * 2010-03-26 2013-06-17 ジ・オハイオ・ステート・ユニバーシティ ｍｉＲ−１５５によるミスマッチ修復およびゲノム安定性の調節に関連する材料および方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
J.IMMUNOL., vol. 183, JPN6016043515, 26 June 2009 (2009-06-26), pages 1091 - 1098, ISSN: 0003641592 *
JOURNAL OF CONTROLLED RELEASE, vol. 107, JPN6017035111, 2005, pages 276 - 287, ISSN: 0003641593 *
LANGMUIR, vol. 23, JPN6016043520, July 2007 (2007-07-01), pages 4498 - 4508, ISSN: 0003641595 *
NUCLEIC ACIDS RESEARCH, vol. 31, no. 11, JPN6017035113, 2003, pages 2717 - 2724, ISSN: 0003641596 *
VACCINE, vol. 29, JPN6016043517, 26 July 2011 (2011-07-26), pages 6911 - 6919, ISSN: 0003641594 *

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11667695B2 (en) 2008-05-16 2023-06-06 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
US12496341B2 (en) 2008-08-28 2025-12-16 Htyr Acquisition Llc Methods for reducing anergy in lymphocytes using modulators of MYC
US11369678B2 (en) 2008-08-28 2022-06-28 Taiga Biotechnologies, Inc. Compositions and methods for modulating immune cells
JP2015519346A (ja) * 2012-05-23 2015-07-09 ジ・オハイオ・ステート・ユニバーシティ アンチセンスオリゴヌクレオチドを送達するための脂質ナノ粒子組成物
US10307490B2 (en) 2012-05-23 2019-06-04 The Ohio State University Lipid nanoparticle compositions for antisense oligonucleotides delivery
US10953048B2 (en) 2012-07-20 2021-03-23 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US10786534B2 (en) 2013-03-11 2020-09-29 Taiga Biotechnologies, Inc. Production and use of red blood cells
JP2019535808A (ja) * 2016-10-17 2019-12-12 南京▲緑▼叶制▲薬▼有限公司 ｂｃｌ−２を抑制するアンチセンスオリゴヌクレオチドの脂質ナノ粒子及びその調製方法
JP2022060418A (ja) * 2016-12-02 2022-04-14 タイガ バイオテクノロジーズ，インク． ナノ粒子製剤
US12344658B2 (en) 2016-12-02 2025-07-01 HTYR Acquistion LLC Nanoparticle formulations
JP2020512282A (ja) * 2016-12-02 2020-04-23 タイガ バイオテクノロジーズ，インク． ナノ粒子製剤
JP7030934B2 (ja) 2016-12-02 2022-03-07 タイガ バイオテクノロジーズ，インク． ナノ粒子製剤
US11116796B2 (en) 2016-12-02 2021-09-14 Taiga Biotechnologies, Inc. Nanoparticle formulations
JP2021038253A (ja) * 2016-12-02 2021-03-11 タイガ バイオテクノロジーズ，インク． ナノ粒子製剤
JP7270085B2 (ja) 2016-12-02 2023-05-09 タイガ バイオテクノロジーズ，インク． ナノ粒子製剤
US10864259B2 (en) 2017-08-03 2020-12-15 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
JP2024105237A (ja) * 2018-04-18 2024-08-06 オイシン バイオテクノロジーズ，インク． 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法
JP7592493B2 (ja) 2018-04-18 2024-12-02 オイシン バイオテクノロジーズ，インク． 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法
JP2021526505A (ja) * 2018-04-18 2021-10-07 オイシン バイオテクノロジーズ，インク． 治療用タンパク質の標的細胞に特異的な産生のための、および、標的細胞に関連する疾患、疾病、または障害の処置のための、融合性脂質ナノ粒子、および、融合性脂質ナノ粒子の製造方法と使用方法
JP7425066B2 (ja) 2018-09-04 2024-01-30 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 核酸を臓器特異的送達するための組成物および方法
JP2024016183A (ja) * 2018-09-04 2024-02-06 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 核酸を臓器特異的送達するための組成物および方法
JP2021535227A (ja) * 2018-09-04 2021-12-16 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム 核酸を臓器特異的送達するための組成物および方法
US12250943B2 (en) 2019-04-08 2025-03-18 Htyr Acquisition Llc Compositions and methods for the cryopreservation of immune cells
US12370217B2 (en) 2019-05-14 2025-07-29 Htyr Acquisition Llc Compositions and methods for treating T cell exhaustion

Also Published As

Publication number Publication date
US20130315937A1 (en) 2013-11-28
EP2852381A2 (en) 2015-04-01
WO2013177415A1 (en) 2013-11-28
EP2852381B1 (en) 2020-10-07
KR20150032944A (ko) 2015-03-31
MX2014014196A (es) 2015-08-14
US20150118288A1 (en) 2015-04-30
JP2015519346A (ja) 2015-07-09
JP6228191B2 (ja) 2017-11-08
WO2013177421A3 (en) 2014-02-27
CN104428005B (zh) 2019-05-10
MX384803B (es) 2025-03-14
AU2013266238A1 (en) 2014-12-18
AU2013266238B2 (en) 2017-07-27
JP6220389B2 (ja) 2017-10-25
AU2013266236A1 (en) 2014-12-18
MX2014014251A (es) 2015-06-17
EP2852415A1 (en) 2015-04-01
EP2852380A4 (en) 2016-01-20
CA2874490C (en) 2021-11-16
US20180021447A1 (en) 2018-01-25
MX353567B (es) 2018-01-18
EP2852380A2 (en) 2015-04-01
KR102169891B1 (ko) 2020-10-26
US20160015824A1 (en) 2016-01-21
BR112014027834A2 (pt) 2017-08-08
CA2871477A1 (en) 2013-11-28
WO2013177419A3 (en) 2014-02-20
WO2013177421A2 (en) 2013-11-28
US9750819B2 (en) 2017-09-05
AU2013266232B2 (en) 2017-08-03
CN104428005A (zh) 2015-03-18
CN104582691A (zh) 2015-04-29
BR112014029247A2 (pt) 2017-06-27
CA2874490A1 (en) 2013-11-28
CN105163721B (zh) 2018-05-22
CA2874495A1 (en) 2013-11-28
AU2017245294A1 (en) 2017-11-02
KR20150020180A (ko) 2015-02-25
JP2015523969A (ja) 2015-08-20
AU2013266232A1 (en) 2014-11-20
WO2013177419A2 (en) 2013-11-28
KR20150032945A (ko) 2015-03-31
EP2852381A4 (en) 2016-01-13
AU2017245294B2 (en) 2019-09-12
US10307490B2 (en) 2019-06-04
JP2018002727A (ja) 2018-01-11
CN105163721A (zh) 2015-12-16

Similar Documents

Publication Publication Date Title
US9750819B2 (en) Lipid nanoparticle compositions and methods of making and methods of using the same
US10555910B2 (en) Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same
JP7515914B2 (ja) 生体内薬物伝達のための脂質ナノ粒子およびその用途
RU2799045C1 (ru) Липидные наночастицы для доставки лекарственного средства in vivo и их применение
Li Development of a QTsome lipid nanoparticle delivery platform for oligonucleotide therapeutics

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160129

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171213

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180122